免疫萤光检测市场规模 - 按产品（抗体、试剂盒和试剂、仪器、消耗品和配件）、类型（间接和直接免疫萤光）、应用（癌症、传染病）、最终用途和预测，2024 - 2032

由于慢性病盛行率不断上升以及对准确和早期诊断工具的需求不断增长，预计免疫萤光检测市场规模在 2024 年至 2032 年期间复合年增长率将达到 5.1%。免疫萤光测定 (IFA) 对于检测和量化与癌症、自体免疫疾病和传染病等疾病相关的特定生物标记至关重要。随着这些疾病的全球发病率持续上升，越来越需要可靠的诊断技术来提供准确和及时的资讯。据世界卫生组织称，到 2050 年，心血管疾病、癌症、糖尿病和呼吸系统疾病等慢性疾病预计每年将导致 9,000 万人死亡。

萤光染料、抗体和检测系统的创新也将增强 IFA 的性能和多功能性，以实现更详细和准确的分析。製药和生技公司对研发活动的投资不断增加，以促进创建具有增强功能的新型免疫萤光解决方案，这将推动市场成长。

整个产业分为产品、类型、应用、最终用途和地区。

从产品来看，由于先进的成像和检测系统在提高这些检测的准确性和效率方面发挥关键作用，仪器领域的 IFA 市场预计将在 2024 年至 2032 年期间显着增长。萤光显微镜、自动成像系统和专用侦测器等精密仪器对于高精度可视化和量化萤光讯号至关重要。

由于对快速、精确的诊断方法来识别和管理传染性病原体的需求不断增加，预计到 2032 年，传染病应用领域的免疫萤光检测产业规模将大幅成长。免疫萤光测定在检测与多种传染病（包括病毒、细菌和寄生虫感染）相关的特定抗原方面非常有效。

由于医疗保健基础设施的不断扩大和研发活动的大量投资，预计亚太地区免疫萤光检测市场将在 2024 年至 2032 年期间大幅成长。生物技术的快速进步和对增强诊断能力的高度重视正在推动对复杂免疫萤光测定的需求。传染病和慢性病负担的日益增加，加上医疗保健支出的增加以及政府改善疾病管理的措施将进一步刺激该区域市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 慢性病盛行率增加
    • 免疫萤光检测技术的进步
    • 不断成长的研发活动
    • 现场检测的采用率不断上升
  • 产业陷阱与挑战
    • 仪器成本高
• 成长潜力分析
• 报销场景
• 监管环境
• 技术景观
  • 核心技术
  • 邻近技术
• 2023 年定价分析
  • 按地区
  • 按关键人物
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

• 主要趋势
• 抗体
• 试剂盒和试剂
• 仪器仪表
• 耗材及配件

第 6 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 间接免疫萤光
• 直接免疫萤光

第 7 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 癌症
• 传染病
• 心血管疾病
• 自体免疫疾病
• 其他疾病

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 学术及研究机构
• 製药和生物技术公司
• 合约研究组织
• 医院和诊断中心

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Danaher Corporation
• EpigenTek Group Inc.
• MaxVision Biosciences Inc.
• Medipan GmbH
• Merck & Co., Inc.
• J. Mitra & Co. Pvt. Ltd.
• Nikon Corporation
• Olympus Corporation
• PerkinElmer, Inc.
• Sino Biological, Inc.
• Thermo Fisher Scientific Inc.
• Werfen

Immunofluorescence assay market size is anticipated to witness 5.1% CAGR between 2024 and 2032 driven by the increasing prevalence of chronic diseases along with the rising demand for accurate and early diagnostic tools. Immunofluorescence assays (IFA) are crucial for detecting and quantifying specific biomarkers associated with diseases, such as cancer, autoimmune disorders, and infectious diseases. As the global incidence of these conditions is continuing to rise, there is growing need for reliable diagnostic techniques to provide precise and timely information. As per WHO, by 2050, chronic diseases, such as cardiovascular conditions, cancer, diabetes, and respiratory illnesses are projected to account 90 million deaths annually.

Innovations in fluorescent dyes, antibodies, and detection systems will also enhance the performance and versatility of IFAs for more detailed and accurate analyses. The increasing investments in R&D activities by pharmaceutical and biotechnology companies for fostering the creation of novel immunofluorescence solutions with enhanced capabilities will drive the market growth.

The overall industry is classified into product, type, application, end-use and region.

Based on product, the IFA market from the instruments segment is slated to witness significant growth during 2024-2032 due to the critical role that advanced imaging and detection systems play in enhancing the accuracy and efficiency of these assays. Sophisticated instruments, such as fluorescence microscopes, automated imaging systems, and specialized detectors are essential for visualizing and quantifying fluorescent signals with high precision.

Immunofluorescence assay industry size from the infectious disease application segment is anticipated to witness substantial growth through 2032 owing to the increasing need for rapid and precise diagnostic methods to identify and manage infectious pathogens. Immunofluorescence assays are highly effective in detecting specific antigens associated with a wide range of infectious diseases, including viral, bacterial, and parasitic infections.

Asia Pacific immunofluorescence assay market is anticipated to grow at a significant pace over 2024-2032 attributed to the expanding healthcare infrastructure and hefty investments in R&D activities. Rapid advancements in biotechnology and the strong emphasis on enhancing diagnostic capabilities are fueling the demand for sophisticated immunofluorescence assays. The growing burden of infectious and chronic diseases, coupled with the rising healthcare expenditure and government initiatives to improve disease management will further stimulate the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases
    • 3.2.1.2 Technological advancements in immunofluorescence assays
    • 3.2.1.3 Growing research and development activities
    • 3.2.1.4 Rising adoption of point-of-care testing
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of instruments
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Technological landscape
  • 3.6.1 Core technologies
  • 3.6.2 Adjacent technologies
• 3.7 Pricing analysis, 2023
  • 3.7.1 By region
  • 3.7.2 By key player
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antibodies
• 5.3 Kits and reagents
• 5.4 Instruments
• 5.5 Consumables and accessories

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Indirect immunofluorescence
• 6.3 Direct immunofluorescence

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cancer
• 7.3 Infectious diseases
• 7.4 Cardiovascular diseases
• 7.5 Autoimmune diseases
• 7.6 Other diseases

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Academic & research institutes
• 8.3 Pharmaceutical & biotechnology companies
• 8.4 Contract research organizations
• 8.5 Hospitals & diagnostic centers

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Agilent Technologies, Inc.
• 10.2 Bio-Rad Laboratories, Inc.
• 10.3 Cell Signaling Technology, Inc.
• 10.4 Danaher Corporation
• 10.5 EpigenTek Group Inc.
• 10.6 MaxVision Biosciences Inc.
• 10.7 Medipan GmbH
• 10.8 Merck & Co., Inc.
• 10.9 J. Mitra & Co. Pvt. Ltd.
• 10.10 Nikon Corporation
• 10.11 Olympus Corporation
• 10.12 PerkinElmer, Inc.
• 10.13 Sino Biological, Inc.
• 10.14 Thermo Fisher Scientific Inc.
• 10.15 Werfen